Harrow Health/$HROW
1D1W1MYTD1Y5YMAX
Capital at risk
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
- Ticker
- $HROW
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 373
- Headquarters
- Nashville, United States
- Website
- www.harrow.com
Harrow Health Metrics
BasicAdvanced
$1.4B
-
-$1.00
0.25
-
Price and volume
Market cap
$1.4B
Beta
0.25
52-week high
$54.85
52-week low
$28.54
Average daily volume
503K
Financial strength
Current ratio
2.244
Quick ratio
1.995
Long term debt to equity
2,019.535
Total debt to equity
2,025.894
Interest coverage (TTM)
-0.12%
Profitability
EBITDA (TTM)
17.715
Gross margin (TTM)
73.28%
Net profit margin (TTM)
-13.51%
Operating margin (TTM)
-1.00%
Effective tax rate (TTM)
-11.36%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
-0.45%
Return on equity (TTM)
-116.07%
Valuation
Price to revenue (TTM)
4.945
Price to book
92.37
Price to tangible book (TTM)
-8.47
Price to free cash flow (TTM)
-99.996
Free cash flow yield (TTM)
-1.00%
Free cash flow per share (TTM)
-0.366
Growth
Revenue change (TTM)
21.05%
Earnings per share change (TTM)
251.19%
3-year revenue growth (CAGR)
38.95%
10-year revenue growth (CAGR)
33.37%
3-year earnings per share growth (CAGR)
21.34%
10-year earnings per share growth (CAGR)
-5.07%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Analyst projections of the future price of Harrow Health stock.
Bulls say / Bears say
Harrow reported Q2 2026 revenue of $70.7 million, up 11% year-over-year and 60% sequentially, underscoring strong demand across its branded eye-care portfolio. (GlobeNewswire)
Harrow’s Q2 2026 revenue of $70.7 million modestly exceeded the IBES consensus estimate of $70.3 million, reflecting resilient core demand amid competitive headwinds. (Reuters)
Harrow’s acquisition of Melt Pharmaceuticals positions MELT-300 on track for NDA submission in the first half of 2027, offering a near-term catalyst and entry into a multi-billion-dollar procedural sedation market. (SEC)
Harrow reported Q2 2026 basic and diluted EPS of −$0.46, missing the consensus estimate of −$0.18 by $0.28, highlighting ongoing profitability challenges. (MarketBeat)
Selling, general and administrative expenses surged to $53.3 million in Q2 2026, up from $33.2 million a year earlier, eroding high gross margins and pressuring free cash flow. (SEC)
ImprimisRx net revenue declined 32% year-over-year to $14.6 million in Q2 2026 due to an exit from the California market and inventory constraints, signaling headwinds in its legacy compounding business. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Harrow Health News
AllArticlesVideos
Funds containing Harrow Health
AllUSDGBPEUR
Fund name | Fund size | $HROW weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.